Shukra Pharmaceuticals Ltd Stock Price Today (NSE: SHUKRAPHAR)
Fundamental Score
Shukra Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shukra Pharmaceuticals Ltd share price today is ₹31.18, up +0.10% on NSE/BSE as of 17 June 2026. Shukra Pharmaceuticals Ltd (SHUKRAPHAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.67K (Cr). The 52-week high for SHUKRAPHAR share price is ₹65.26 and the 52-week low is ₹12.97. At a P/E ratio of 139.49x, SHUKRAPHAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.90% and a debt-to-equity ratio of 0.06.
Shukra Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Shukra Pharmaceuticals Ltd share price chart: -9.74% return over the past month. 52-week high ₹65.26, 52-week low ₹12.97.
Shukra Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹29.89 | ₹29.89 | ₹28.52 | ₹29.12 | 3.36L (Cr) | |
| ₹29.00 | ₹29.98 | ₹29.00 | ₹29.14 | 96.50K (Cr) | |
| ₹29.09 | ₹29.45 | ₹28.44 | ₹28.99 | 3.46L (Cr) | |
| ₹27.23 | ₹28.58 | ₹26.30 | ₹28.09 | 4.06L (Cr) | |
| ₹28.50 | ₹28.98 | ₹27.01 | ₹27.23 | 3.74L (Cr) | |
| ₹29.01 | ₹29.88 | ₹27.59 | ₹28.02 | 4.66L (Cr) | |
| ₹30.16 | ₹30.95 | ₹28.90 | ₹29.00 | 5.72L (Cr) | |
| ₹30.00 | ₹31.50 | ₹29.80 | ₹30.16 | 1.56L (Cr) | |
| ₹30.19 | ₹31.00 | ₹29.35 | ₹30.08 | 1.10L (Cr) | |
| ₹30.35 | ₹30.98 | ₹29.01 | ₹30.34 | 1.82L (Cr) |
Shukra Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹29.00 | ₹29.98 | ₹28.52 | ₹29.12 | +0.41% | |
| ₹29.38 | ₹35.30 | ₹26.30 | ₹28.99 | -1.33% | |
| ₹30.34 | ₹36.85 | ₹28.13 | ₹29.07 | -4.19% | |
| ₹39.20 | ₹45.33 | ₹30.34 | ₹30.34 | -22.60% | |
| ₹39.18 | ₹46.79 | ₹34.15 | ₹41.24 | +5.26% | |
| ₹56.29 | ₹58.99 | ₹38.59 | ₹40.51 | -28.03% | |
| ₹38.68 | ₹65.26 | ₹36.70 | ₹59.25 | +53.18% | |
| ₹40.19 | ₹44.31 | ₹35.73 | ₹38.68 | -3.76% | |
| ₹35.15 | ₹42.70 | ₹32.44 | ₹41.01 | +16.67% | |
| ₹25.70 | ₹35.86 | ₹25.70 | ₹35.86 | +39.53% | |
| ₹21.49 | ₹26.22 | ₹17.06 | ₹26.22 | +22.01% | |
| ₹15.05 | ₹22.45 | ₹13.63 | ₹21.11 | +40.27% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Shukra Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shukra Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SHUKRAPHAR across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (15.90%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.15%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (340.74%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (22.45% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (243.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (243.61% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (14.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (50.96%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 139.49x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 0.11%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Shukra Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Shukra Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Shukra Pharmaceuticals LtdShukra Pharmace...Selected✓ SHUKRAPHAR • 524632 | 62.1/100 | ₹31.18₹31 | ₹1668.32₹1668.32 | 139.49Average 139.5 Average | 15.90%Good 15.90% Good | 21.80%Excellent 21.80% Excellent | 0.06Excellent 0.1 Excellent | 243.61%Excellent 243.61% Excellent | 22.45%Excellent 22.45% Excellent | 0.03% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Shukra Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for SHUKRAPHAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹4.23 | ₹13.64 | 3.2x |
| FY 2023 | ₹0.66 | ₹3.09 | 4.7x |
| FY 2022 | ₹0.02 | ₹3.30 | 132.5x |
| FY 2021 | ₹0.01 | ₹2.08 | 333.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Shukra Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by SHUKRAPHAR — dividend yield 0.03%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹4.38 Cr |
| FY 2024 | ₹0.07 Cr |
| FY 2023 | ₹0.07 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Shukra Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for SHUKRAPHAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.76%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
340.74%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
22.45%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
243.61%
Compounded annual net profit growth over 5 years
Shukra Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SHUKRAPHAR — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Shukra Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Shukra Pharmaceuticals Ltd (SHUKRAPHAR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Shukra Pharmaceuticals Ltd
About SHUKRAPHAR (Shukra Pharmaceuticals Ltd)
Shukra Pharmaceuticals Ltd is an Indian pharmaceutical company focused on developing, manufacturing, and selling a broad range of medicines both in India and to other countries. Th...ey create and market various types of drugs, including those that fight infections like bacteria and fungi, as well as treatments for malaria, viruses, and parasitic worms. Their product range also extends to medicines for mental health conditions such as depression and anxiety, and treatments for common ailments like ulcers and high blood pressure. The company's main business areas are centered around providing affordable and accessible medicines across diverse therapeutic categories. They make many kinds of products including antibiotics (like penicillin), vitamins, and medications for allergies, diabetes, and tuberculosis. This wide variety helps them reach different segments of the healthcare market and cater to many patient needs. While not one of the very largest pharmaceutical companies, Shukra Pharmaceuticals holds a significant position in the Indian market by supplying essential medicines. Based in Ahmedabad, the company has been operating since 1993 and continues to develop and distribute pharmaceutical products aimed at improving health outcomes. They aim to continue their growth within India's competitive pharmaceuticals sector.
Company Details
Key Leadership
Corporate Events
SHUKRAPHAR Share Price: Frequently Asked Questions
What is the current share price of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) trades at ₹31.18 on NSE and BSE. Market cap ₹1.67K (Cr). Educational data only.
What is the P/E ratio of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd has a P/E of 139.49x vs industry average 31.77x.
What is the Bull Run score for Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd has a Bull Run score of 62.1/100 based on 25+ financial parameters.
Does Shukra Pharmaceuticals Ltd pay dividends?
Shukra Pharmaceuticals Ltd has a dividend yield of 0.03%. Past dividends don't guarantee future payments.
What is the ROE of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd has ROE of 15.90%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd has debt-to-equity of 0.06.
Is Shukra Pharmaceuticals Ltd a good investment?
Bull Run gives Shukra Pharmaceuticals Ltd a score of 62.1/100. This is not investment advice — consult a SEBI-registered advisor.